Zimmer Biomet (ZBH) Projected to Announce Quarterly Earnings on Wednesday

Zimmer Biomet (NYSE:ZBH) will likely be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of $2.01 per share and revenue of $2.1350 billion for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same quarter last year, the company posted $1.81 earnings per share. The business’s revenue was up 9.3% on a year-over-year basis. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded up $0.56 during trading hours on Wednesday, hitting $96.31. 307,134 shares of the company were exchanged, compared to its average volume of 2,278,613. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The business has a 50-day moving average of $88.23 and a 200-day moving average of $89.79. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $108.29. The stock has a market capitalization of $18.63 billion, a price-to-earnings ratio of 25.10, a P/E/G ratio of 2.71 and a beta of 0.46.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is 24.94%.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.28% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

Institutional investors have recently added to or reduced their stakes in the business. DV Equities LLC purchased a new position in Zimmer Biomet during the fourth quarter worth about $25,000. Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet in the 4th quarter valued at about $31,000. Headlands Technologies LLC acquired a new position in shares of Zimmer Biomet during the 2nd quarter valued at about $37,000. EFG International AG acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at about $55,000. Finally, Mpwm Advisory Solutions LLC purchased a new position in shares of Zimmer Biomet during the 3rd quarter worth about $65,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZBH has been the subject of a number of research analyst reports. Robert W. Baird set a $92.00 price target on shares of Zimmer Biomet in a report on Wednesday, April 29th. Zacks Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday. Wells Fargo & Company dropped their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, April 29th. Truist Financial reiterated a “hold” rating and set a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. decreased their price target on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, twelve have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average price target of $102.00.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.